WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406718

CAS#: 537034-17-6

Description: BML-210, also known as CAY10433, is HDAC inhibitor. BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. BML-210 can inhibit cell growth and induce apoptosis in cervical cancer cells, what correlates with down-regulation of HDAC class I and II and changes in the DAPC expression levels.

Price and Availability

Size Price Shipping out time Quantity
25mg USD 150 2 weeks
50mg USD 250 2 weeks
100mg USD 450 2 weeks
200mg USD 750 2 weeks
500mg USD 1250 2 weeks
1g USD 1950 2 weeks
2g USD 2950 2 weeks
5g USD 4250 2 weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

BML-210, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406718
Name: BML-210
CAS#: 537034-17-6
Chemical Formula: C20H25N3O2
Exact Mass: 339.1947
Molecular Weight: 339.439
Elemental Analysis: C, 70.77; H, 7.42; N, 12.38; O, 9.43

Synonym: BML-210; BML 210; BML210; CAY10433; CAY-10433; CAY 10433.

IUPAC/Chemical Name: N-(2-aminophenyl)-N'-phenyl-octanediamide


InChi Code: InChI=1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Borutinskaitė V, Navakauskienė R. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug 6;16(8):18252-69. doi: 10.3390/ijms160818252. PubMed PMID: 26287160; PubMed Central PMCID: PMC4581243.

2: Borutinskaite VV, Magnusson KE, Navakauskiene R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep. 2012 Dec;39(12):10179-86. doi: 10.1007/s11033-012-1892-5. Epub 2012 Sep 26. PubMed PMID: 23007576.

3: Savickiene J, Treigyte G, Jazdauskaite A, Borutinskaite VV, Navakauskiene R. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling. Cell Biol Int. 2012 Nov 1;36(11):1067-78. doi: 10.1042/CBI20110649. PubMed PMID: 22845560.

4: Savickiene J, Treigyte G, Borutinskaite VV, Navakauskiene R. Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells. Cell Mol Biol Lett. 2012 Dec;17(4):501-25. Epub 2012 Jul 20. PubMed PMID: 22820861.

5: Jayathilaka N, Han A, Gaffney KJ, Dey R, Jarusiewicz JA, Noridomi K, Philips MA, Lei X, He J, Ye J, Gao T, Petasis NA, Chen L. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul;40(12):5378-88. doi: 10.1093/nar/gks189. Epub 2012 Mar 6. PubMed PMID: 22396528; PubMed Central PMCID: PMC3384312.

6: Xiong P, Li YX, Tang YT, Chen HG. Proteomic analyses of Sirt1-mediated cisplatin resistance in OSCC cell line. Protein J. 2011 Oct;30(7):499-508. doi: 10.1007/s10930-011-9354-9. PubMed PMID: 21947960.

7: Savickiene J, Treigyte G, Jonusiene V, Bruzaite R, Borutinskaite VV, Navakauskiene R. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells. Mol Cell Biochem. 2012 Jan;359(1-2):245-61. doi: 10.1007/s11010-011-1019-7. Epub 2011 Aug 13. PubMed PMID: 21842375.

8: Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors. Ann N Y Acad Sci. 2009 Aug;1171:321-33. doi: 10.1111/j.1749-6632.2009.04718.x. PubMed PMID: 19723072.

9: Borutinskaite VV, Navakauskiene R, Magnusson KE. Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells. Ann N Y Acad Sci. 2006 Dec;1091:346-55. PubMed PMID: 17341627.

10: Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol. 2006 Nov 7;549(1-3):9-18. Epub 2006 Aug 15. PubMed PMID: 16978604.

11: Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol. 2006 Oct;2(10):551-8. Epub 2006 Aug 20. Erratum in: Nat Chem Biol. 2007 Jul;3(7):432. PubMed PMID: 16921367.